Dow Jones
37.981,45 -479,47 (-1,25%) Nasdaq
15.529,25 -183,50 (-1,17%) Nikkei 225
37.628,48 -831,60 (-2,16%) EUR/USD
1,0733 +0,0032 (+0,30%) Bitcoin EUR
60.034,91 -224,89 (-0,37%) CMC Crypto 200
1.386,45 +3,88 (+0,28%)
NVN Liquidation, Inc. (0A4P.L)
| Chiusura precedente | 0,0008 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 425 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,65 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,8930 |
| Prossima data utili | 25 apr 2024 - 28 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNovan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – Agreement provides a path forward for a product, if appro
- GlobeNewswire
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current
- GlobeNewswire
Novan Focuses Strategic Direction and Announces Restructuring
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental st
